Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer | Zendy

Jochen H. Lorch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer

Author(s) -

Jochen H. Lorch

Publication year - 2009

Publication title -

cancer management and research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.024

H-Index - 40

ISSN - 1179-1322

DOI - 10.2147/cmr.s5134

Subject(s) - squamous cell cancer , medicine , head and neck , oncology , head and neck cancer , epidermal growth factor receptor , cancer , cancer research , surgery

Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research